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Objective To determine the feasibility and utility of using media reports and other open-source information collected by the Global Public
Health Intelligence Network (GPHIN), an event-based surveillance system operated by the Public Health Agency of Canada, to rapidly detect
clusters of adverse drug events associated with ‘novel psychoactive substances’ (NPS) at the international level.
Methods and Results Researchers searched English media reports collected by the GPHIN between 1997 and 2013 for references to
synthetic cannabinoids. They screened the resulting reports for relevance and content (i.e., reports of morbidity and arrest), plotted and
compared with other available indicators (e.g., US poison control center exposures). The pattern of results from the analysis of GPHIN reports
resembled the pattern seen from the other indicators.
Conclusions The results of this study indicate that using media and other open-source information can help monitor the presence, usage,
local policy, law enforcement responses, and spread of NPS in a rapid effective way. Further, modifying GPHIN to actively track NPS
would be relatively inexpensive to implement and would be highly complementary to current national and international monitoring efforts.
© 2015 The Authors. Human Psychopharmacology: Clinical and Experimental published by John Wiley & Sons, Ltd.
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INTRODUCTION
Sometimes referred to as “legal highs,” “designer
drugs,” “research chemicals,” or “herbal highs,” the
umbrella term novel psychoactive substances (NPS)
is used to refer to psychoactive drugs that have not
been approved for therapeutic use and that are not
listed under the 1971 United Nations Convention on
Psychotropic Substances. Although they might be nat-
ural substances (e.g., Salvia divinorum and kratom),
they are frequently synthetic agents marketed as legal
substitutes for more common illicit drugs. NPS are
advertised and generally sold via the Internet or in
“head shops” and are often uncontrolled (or were not
controlled when they emerged) by relevant drug
legislation. Information about the effects and any
associated short-term or long-term harms of these
substances in humans is typically limited.
A recent report by the United Nations Ofﬁce on
Drugs and Crime describes the rapid emergence of
these drugs as a serious threat to public health (United
Nations Ofﬁce On Drugs And Crime, 2013). As of
2013, the European Monitoring Centre for Drugs and
Drug Addiction early warning system was monitoring
over 350 new drugs of which almost 250 had been ﬁrst
identiﬁed since 2010 (European Monitoring Centre for
Drugs and Drug Addiction 2014).
CHALLENGES OF MONITORING USE
Monitoring NPS poses a number of unique challenges.
The rapid appearance of new substances on the mar-
ket, the variety of brand names associated with the
products, the assortment of chemicals frequently found
in any one product, and the short life cycle of any spe-
ciﬁc product all contribute to the challenges of using
conventional strategies for monitoring the emergence
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of and harms associated with NPS use (for a review of
the strategies that have been used to determine the
epidemiology of NPS, see Sumnall, McVeigh, &
Evans-Brown, 2013).
General population surveys or other self-reporting
measures are limited in their ability to detect NPS
because of the time it takes to develop and add
appropriate questions on the survey, as well as to
collect and analyze the data. By the time survey
results are released, the product could have already
caused a substantial amount of harm, the chemical
composition of the product might have changed,
or the product might have disappeared from the
marketplace.
Data from medical monitoring systems have also
been used to monitor use of NPS and are particularly
effective at assessing harms: for example, emergency
department visits to hospitals (Substance Abuse and
Mental Health Services Administration, 2012) and
calls to poison control centers (American Association
of Poison Control Centers, 2014). However, not all
countries have medical monitoring systems that assess
morbidity related to the use of psychoactive drugs.
The emergence of NPS can also be monitored
through forensic analysis of samples seized by law
enforcement, acquired via test purchases, or donated
during amnesties or in response to harm reduction
strategies. This method of monitoring the emergence
of NPS is invaluable as it is the only reliable way to
know with certainty what substances are present in
the marketplace. However, these methods can be ex-
pensive, and laboratories can have difﬁculty determin-
ing the chemical compounds contained in a product
because of the novelty of the active ingredient and
the lack of a reference substance to make a reliable
identiﬁcation or because of the various mixtures of
compounds the sample might contain.
These monitoring strategies help to provide informa-
tion that can be pieced together to understand the epi-
demiology of NPS. However, not all countries have
the resources and capabilities to implement some or
all of them. Because the approaches vary from one
country to another, estimates regarding the prevalence
of use and harms associated with use are problematic,
and it is currently not possible to make international
comparisons (Sumnall et al., 2013).
Given the rapid emergence of NPS as well as lim-
ited capabilities for monitoring their emergence, those
seeking to monitor NPS have had to innovate and
look to new data sources that could, in combination
with existing sources, help to provide a better under-
standing of the epidemiology of NPS (e.g., Corazza,
Assi, Simonato, & the ReDNet group, 2014; Deluca
et al., 2012). These data sources have included Inter-
net monitoring strategies.
The Internet has played an important role in the devel-
opment, marketing, and sale of NPS. Similarly, Internet
monitoring has quickly become an important source of
information on NPS. Internet monitoring has been used
predominantly to identify and track new substances by
examining websites that sell NPS (Bruno, Poesiat, &
Matthews, 2013). In addition to monitoring online sales
of NPS, another rich source of information has come
from online message boards or discussion forums where
anonymous users discuss drug use (Davey et al., 2012;
Deluca et al., 2012; McNaughton et al., 2012).
Although used to track the spread of infectious
diseases since 2002, media reports and other open-
source information have yet to be appropriated to
monitor NPS.
THE GLOBAL PUBLIC HEALTH INTELLIGENCE
NETWORK
Operated and developed by the Public Health
Agency of Canada for the World Health Organiza-
tion, the Global Public Health Intelligence Network
(GPHIN) monitors news sources and websites across
the globe 24h a day, 7 days a week, in nine lan-
guages (English, French, Farsi, Portuguese, Arabic,
Russian, Spanish, and Chinese, simpliﬁed and tradi-
tional) to provide alerts about international events of
public health signiﬁcance to both domestic and
international partners (Mawudeku & Blench, 2005;
Keller et al., 2009). The GPHIN has been shown
to effectively detect rumors of unusual disease
events. These rumors (i.e., open-source media
reports) are then veriﬁed by the appropriate authori-
ties. Of the 578 disease outbreaks veriﬁed by the
World Health Organization between July 1998 and
August 2001, 324 or 56% were initially detected
by the GPHIN (Heymann et al., 2001).
The GPHIN monitors open-source media automati-
cally as well as manually. Filtered via a series of
queries, the GPHIN application automatically retrieves
articles from news feed aggregators that contain key-
words indicating the article might be relevant to public
health security. When the article enters the GPHIN
system, it is also automatically assigned a “relevancy
score.” Highly relevant articles are retained while
highly irrelevant articles are excluded. In addition to
automatic ﬁltering and relevancy assessment, the
GPHIN also relies on human analysts. Articles that
are not deemed to be either highly relevant or irrele-
vant by the automated process are reviewed by a
GPHIN analyst. The analyst employs his or her
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linguistic, interpretive, and analytical expertise to de-
termine inclusion or exclusion from the GPHIN data-
base. Articles retained in the GPHIN database are
categorized into one or more of the GPHIN’s taxonomy
categories (animal or human infectious diseases, plant
diseases, natural disasters, chemical incidents, radio-
logical incidents, nuclear incidents, and unsafe
products).
USING MEDIA TO MONITOR CLUSTERS OF
ADVERSE DRUG EVENTS ASSOCIATED
WITH NPS
As part of its mandate to gather information on unsafe
products, information on some NPS and new drug use
trends are retained in the GPHIN database (e.g., syn-
thetic cathinones and caffeinated alcoholic beverages).
The objective of the current study was to determine the
feasibility of using this information to monitor and
detect clusters of adverse drug events associated with
NPS. To do so, we pilot-tested the methodology by
examining English media reports on synthetic cannabi-
noid receptor agonists from 1997 to June 2013.
Synthetic cannabinoids
Synthetic cannabinoids are a large and diverse group
of psychoactive drugs that, since approximately
2008, have been marketed for recreational use as legal
alternatives to cannabis. This group of drugs is more
correctly referred to as cannabinoid receptor agonists
or cannabimimetics. However, they have also been
referred to as Δ9-tetrahydrocannabinol (THC) homo-
logues, synthetic marijuana, legal weed, and so on.
Synthetic cannabinoids are functionally similar to
THC, the main psychoactive ingredient in cannabis.
As of May 2013, there have been over 84 different
synthetic cannabinoids identiﬁed internationally
(European Monitoring Centre for Drugs and Drug
Addiction, 2013). Synthetic cannabinoids are typically
purchased online or via the black market. They are
then dissolved and sprayed on dried plant material
(e.g., marshmallow, mullien, or damiana leaves) so
that the end product appears less synthetic and more
“herbal” or “natural.” The sprayed plant is then placed
in small packets, branded with names such as “Spice,”
“K2,” “IZMS,” and so on, and sold as “herbal incense”
or “herbal smoking blends.”
METHODS AND RESULTS
Search strategy
To identify media reports in the GPHIN database that re-
ferred to synthetic cannabinoids or other similar synthetic
preparations, we developed a speciﬁc search query. The
GPHIN database contains or references articles from
January 1997, so the query spanned January 1997 to
July 2013; it employed the following search string:
“synthetic cannabinoids” OR “synthetic cannabis”
OR “synthetic marijuana” OR “synthetic weed”
OR “synthetic pot” OR “synthetic grass” OR “syn-
thetic THC” OR “fake cannabis” OR “fake mari-
juana” OR “fake weed” OR “fake pot” OR “legal
weed” OR “legal pot” OR “legal blends” OR
“cannabimimetics” OR “legal highs” OR “herbal
highs” OR “herbal blends” OR “herbal incense”
OR “herbal mixtures” OR “herbal smoking blends”
OR “synthetic cannabinoid” OR “legal blend” OR
“cannabimimetic” OR “legal high” OR “herbal
high” OR “herbal blend” OR “herbal mixture” OR
“herbal smoking blend.”
Relevance screening and data extraction
The search yielded 840 media reports. Each report was
examined for relevancy by a member of the research
team. Speciﬁcally, the following question was asked
of each media report: “Is this a media report that refers
to synthetic cannabinoids or other similar synthetic
preparations?” Reports for which the question was
answered in the negative were excluded. This stage
of screening excluded 36% (317 reports; see Figure 1).
Following screening, two reviewers extracted the
following information from the remaining reports: (1)
headline; (2) publication date; (3) whether the report
was a repetition of another included story; (4) topic
of the media report; and (5) if the report referred to a
speciﬁc event, the location of the event. When it was
not possible to determine the speciﬁc location of the
event, the location of the media outlet was recorded.
As illustrated in Figure 1, after removing duplicates,
data was extracted from 490 unique reports related to
synthetic cannabinoids.
When determining the topic of the media report,
researchers manually coded each report into one only
of the following categories:
• Seizure/arrest: reports covering arrests or seizures
of synthetic cannabinoids.
• Morbidity/mortality involving the drug: reports of
direct or indirect harms associated with synthetic
cannabinoid use.
• General report of presence: reports that did not refer
to a speciﬁc event, but instead contained anecdotal
information from local sources about the presence of
synthetic cannabinoids in the community.
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• Health alert/warning of new product: reports
covering local alerts by public health or law enforce-
ment about the presence of synthetic cannabinoids.
• New law/policy announcement: reports of new
legislation or policy pertaining to the sale or posses-
sion of synthetic cannabinoids.
• Opinion/editorial: reports that included opinions,
commentary, or other editorial material.
• Results of research report: reports that referred to
recent results of research involving synthetic
cannabinoids.
• Prevention/harm reduction initiative: reports
referring to a new or ongoing prevention or harm
reduction initiative.
• New method/test to detect: reports describing a new
method to detect synthetic cannabinoids.
• Report of trial: reports of a trial for possession or
trafﬁcking of synthetic cannabinoids. These catego-
ries emerged from the data and were not speciﬁed
a priori. The most frequently occurring reports were
those announcing new policies or laws followed by
reports of seizures or arrests (see Table 1).
After reports were categorized, reports that did not re-
fer to a speciﬁc adverse drug event that could be linked
to a speciﬁc time and place (i.e., opinion/editorials,
results of research reports, prevention/harm reduction
initiatives, or reports of newmethod/test to detect) were
removed. There were 177 unique reports referring to
speciﬁc events (see Figure 1).
Number and category of media reports over time
To begin, we plotted the number of reports referring to
synthetic cannabinoids in the English media over time
(see Figure 2). The ﬁrst media reports emerged in late
2009, early 2010, and there were very few (<10 per
month). The number of reports increased in early
2012, peaking in April 2013.
Comparison with other indicators of synthetic
cannabinoid use
In an effort to determine if the number of media reports
about synthetic cannabinoids is a valid indicator of
synthetic cannabinoid-related adverse drug events, we
next compared our results with other indicators to de-
termine whether they had concurrent validity. If the
number of media reports about synthetic cannabinoids
is a valid measure of synthetic cannabinoid-related ad-
verse drug events, then the resulting pattern or curve
when plotted over time should resemble that of other
indicators of use or harms associated with use. To as-
sess the extent to which the pattern of media reports
of synthetic cannabinoid use resemble other indicators,
we compared the pattern to the number of U.S. poison
control center exposures and the volume of discussion
regarding synthetic cannabinoids in the online harm
reduction discussion forum Bluelight (now moved to
www.bluelight.org).
Figure 1. Diagram illustrating the reports yielded by the query and how they were screened for relevancy
Table 1. Frequency of media report topics
Report Topic Frequency Percentage (%)
New law/policy announcement 190 39
Seizure/arrest 54 11
Opinion/editorial 50 10
Morbidity involving the drug 48 10
Results of research report 43 9
General report of presence 43 9
Health alert/warning of new product 33 7
Prevention/harm reduction initiative 16 3
Method/test to detect 8 2
Report of trial 5 1
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Poison control center exposures. Figure 3 includes a
graph of the number of U.S. poison control center calls
about synthetic cannabinoids between January 2010
and June 2013, and a graph of the number of media re-
ports during the same time. A visual comparison of the
juxtaposed graphs indicates that poison control center
calls began increasing slowly in January 2010, peaked
in July 2011, and then gradually decreased. Media
reports appear to lag poison control center calls by
6–8months, then gradually decrease in number (when
speciﬁcally examining morbidity presence, seizure/
arrest, and health alerts). This comparison indicates
that while media reports of synthetic cannabinoids
might not be as sensitive as poison control center calls,
there is a comparable pattern in the time frame
examined.
Volume of discussion on bluelight.ru. To further as-
sess the extent to which the frequency of media reports
was comparable with other indicators of synthetic
cannabinoid use, we compared the number of media
reports with the volume of discussion referring to
Figure 2. Number of reports referring to synthetic cannabinoids in English media between January 2010 and June 2013
Figure 3. Comparison of number of US poison control center exposure calls (reproduced and adapted with permission from University of Maryland, Center
for Substance Abuse Research, 2013) and number of US media reports regarding synthetic cannabinoids between January 2010 and June 2013
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synthetic cannabinoids on the harm reduction forum,
Bluelight. Among other roles (e.g., summarizing infor-
mation on drugs), Bluelight is an online discussion
forum in which users discuss recreational drug use.
Plahuta (2013) analyzed approximately 1.2 million
posts on the discussion forum and produced a custom-
izable chart that permits users to plot, over time, the
proportion of discussions containing reference to over
100 different drugs.
Figure 4 includes the proportion of discussion posts
referring to synthetic cannabinoids relative to all
monthly posts. In the succeeding text is a graph of
the number of reports about synthetic cannabinoids in
the English media. A visual comparison reveals great
similarity in the curves. Both charts indicate low levels
of activity, until December 2011–January 2012. Both
graphs contain two time periods where the level of
activity peaks, the ﬁrst around March 2012, the second
in July 2012.
DISCUSSION
To the best of our knowledge, this study is the ﬁrst to
employ media reports and other open-source informa-
tion to monitor NPS. The purpose of the study was to
determine the feasibility of using information collected
by GPHIN to detect adverse drug events associated
with NPS. To do so, the number of media reports about
synthetic cannabinoids captured by GPHIN was plotted
over time. The pattern of results was then compared
with other indicators of synthetic cannabinoid pres-
ence, namely, US poison control center exposures and
discussion about synthetic cannabinoids on the harm
reduction discussion forum Bluelight. That the appear-
ance of media reports on synthetic cannabinoids in the
U.S. appears to lag poison control center calls is not
surprising. Poison center calls are a leading edge indi-
cator of harms associated with new drugs (American
Association of Poison Control Centers, 2014). How-
ever, not all countries or regions have timely access to
data from poison centers. In the absence of access to
other early warning indicators, it could be that media
reports are one of the ﬁrst indicators available to local
public health authorities of signiﬁcant harms arising
from psychoactive substance use.
Further use of media reports to monitor NPS has a
number of advantages. First, it could be especially
helpful in identifying clusters of drug use that are as-
sociated with great harm. Although media reports
can have many limitations (e.g., often sensationalist
and can frequently include incorrect information re-
garding substances involved), they can be valuable
in identifying clusters of harms related to substance
use that warrant further investigation. Therefore,
Figure 4. Comparison between the proportion of posts referring to synthetic cannabinoids relative to all monthly posts on the drug forum Bluelight.ru (data
from Plahuta, 2013), and the number of reports regarding synthetic cannabinoids in the English media between January 2010 and June 2013
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media reports could provide a vitally important early
signal that could be used in an event-based surveil-
lance system to monitor and report on signiﬁcant clus-
ters of morbidity or mortality related to psychoactive
substance use.
Event-based surveillance is used to monitor infec-
tious disease outbreaks (World Health Organization,
2008). However, we are unaware of any such system
that has been developed to monitor drug-related harms.
Such a system would be highly complementary to
existing national drug early warning systems. In addi-
tion to being a valuable early indicator of clusters of
harms related to substance use, the proposed system
would also require relatively little investment of re-
sources. Because GPHIN already has the infrastructure
in place for monitoring other public health threats,
modifying the system to actively track NPS would be
relatively inexpensive. Another possible advantage of
this system would be that countries participating in
such a system could monitor substance use-related
harms occurring outside their borders. The implemen-
tation of such a system could facilitate rapid knowledge
exchange between authorities who have experience re-
garding a speciﬁc NPS or new drug use trend and those
who are ﬁrst encountering it.
The GPHIN system is also complimentary to and of-
fers a number of advantages over other web analytical
software that are increasingly being used in health
research. One prominent example is Google Trends
(Nuti et al., 2014). Analyses obtained from a tool such
as Google trends are a useful indicator of the public’s
interest in a speciﬁc topic, as represented by the
volume of speciﬁc keywords or search terms used over
time. However, the utility of the strategy in determin-
ing prevalence of or harms associated with NPSs is
limited because search engine query data simply
reﬂects public interest in a topic/drug. While in some
circumstances this may be a reliable proxy for drug
use or harms associated with use, there are many situ-
ations when it may not. For example, in June 2012,
there was a dramatic increase in searches for the string
“bath salts” (a slang term used in Canada and the
United States to refer to a mixture of various synthetic
cathinones) among Canadians. However, this sudden
increase in interest was not associated changes in use
or harms associated with use of “bath salts” (Canadian
Community Epidemiology Network On Drug Use,
2012). Instead, the sudden increase in public interest
in the drug was more likely the result of a sensational
story out of Miami, Florida, of a man who cannibal-
ized another man on a public freeway who was report-
edly on “bath salts” (these reports were never
conﬁrmed). In contrast to public interest in a drug,
the GPHIN system tracks media stories about events
(e.g., seizures/arrests, morbidity/mortality involving
the drug, and health alert/warning of new product)
and thus provides more information that could be used
along with Google Trends data to monitor NPS.
Limitations
Limitations of the design. The GPHIN system is cur-
rently not designed or conﬁgured to be sensitive to
NPS-related media. It is unknown to what extent
media reports on synthetic cannabinoids were ﬁltered
out before entering into the GPHIN database. In an
attempt to approximate how many reports might have
been ﬁltered out, GPHIN staff ran the same query on
the unﬁltered source data from the news aggregator,
Factiva. This query returned 35342 records. If we
assume a similar rate of relevance to what was found
in the pilot data (i.e., approximately 50%), there could
be up to 17000 potentially relevant records.
Limitations of language. Although the GPHIN system
operates in nine languages (English, French, Farsi,
Portuguese, Arabic, Russian, Spanish, and Chinese,
simpliﬁed and traditional), for this study, only English
reports were included. Additional languages would
likely increase the volume of relevant reports and could
improve timeliness of detection where NPS use is asso-
ciated with non-English countries or communities
Query limitations. The query we used to identify
media reports in the GPHIN database that referred to
synthetic cannabinoids or other similar synthetic prep-
arations did not include street names (e.g., “Spice” or
“K2”) or speciﬁc chemical names (e.g., “JWH-018”).
However, we argue that the proposed system is not de-
signed to detect mentions of speciﬁc chemicals or drug
brands as these will frequently be unknown at the time
of the event. Instead, the strength of the proposed sys-
tem lies in its capacity to detect clusters of adverse
drug events associated with larger categories of new
drugs (e.g., cathinones and phenethylamines) as they
appear on the market. Media reports would be another
indicator for drug use epidemiologists to examine in
conjunction with other early warning indicators to help
validate the reports (e.g., poison control center data,
emergency room data, wastewater drug analysis, and
Internet monitoring of sites selling NPS). Ideally, clus-
ters of adverse drug events would be followed up with
more reliable methods to determine the exact
chemicals involved such as urine screens, analysis of
seized samples, and so on. Although search queries
would undoubtedly require updating on an ongoing
basis, queries would not need to include speciﬁc terms
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for speciﬁc new chemicals or brands introduced into
the market in order to detect and alert the user of the
system to clusters of adverse drug events.
Despite the limitations, the pilot study indicates the
proposed system is worth further investigation. Work
must be conducted to make the network more sensitive
to NPS and ensure all media reports about NPS are
entered into the GPHIN database. In addition, a multi-
lingual taxonomy must be developed that is sensitive
to emerging NPS in real time. A multilingual taxon-
omy could map the terms across languages so a search
in one language only (e.g., English) would be able to
capture occurrences in all languages. To be an effec-
tive complement to existing monitoring efforts, it is
essential that the methods be tested in multiple
languages and across multiple substances as well as
new, possibly yet unknown, substances.
CONCLUSIONS
The results of this initial pilot study indicate that using
media and other open-source information shows great
promise for rapidly tracking the presence, usage, local
policy, law enforcement responses, and spread of NPS.
Further, modifying GPHIN to actively track NPS
would be relatively inexpensive to implement and
could be highly complementary to current national
and international monitoring efforts.
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